Anetumab ravtansine is an antibody–drug conjugate (ADC) comprised of a humanized anti-mesothelin antibody conjugated to DM4 (a maytansinoid tubulin inhibitor), which showed potent killing of tumor cells expressing mesothelin [87]. The gene discussed is MSLN; the disease is neoplasm.